Tian Zhang

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2009

Harvard Medical School

Internal Medicine Residency, Medicine

Duke University School of Medicine

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Significant Contributor
Start Date
End Date

CTC-Immune Checkpoints

Administered By
Duke Cancer Institute
Role
Co-Principal Investigator
Start Date
End Date

Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

Administered By
Medicine, Medical Oncology
Awarded By
V Foundation for Cancer Research
Role
Principal Investigator
Start Date
End Date

Mirati 516-003

Administered By
Duke Cancer Institute
Awarded By
Mirati Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).

Authors
Zhang, T; Austin, RG; Park, SE; Runyambo, D; Boominathan, R; Rao, C; Bronson, E; Anand, M; Healy, P; George, DJ; McNamara, MA; Armstrong, AJ
MLA Citation
Zhang, Tian, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC)..” Journal of Clinical Oncology, vol. 36, no. 6_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 191–191. Crossref, doi:10.1200/jco.2018.36.6_suppl.191.
URI
https://scholars.duke.edu/individual/pub1364812
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
36
Published Date
Start Page
191
End Page
191
DOI
10.1200/jco.2018.36.6_suppl.191

Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.

Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416 For further resources related to this article, please visit the WIREs website.
Authors
Caster, JM; Patel, AN; Zhang, T; Wang, A
MLA Citation
Caster, Joseph M., et al. “Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials..” Wiley Interdiscip Rev Nanomed Nanobiotechnol, vol. 9, no. 1, Jan. 2017. Pubmed, doi:10.1002/wnan.1416.
URI
https://scholars.duke.edu/individual/pub1134780
PMID
27312983
Source
pubmed
Published In
Wiley Interdiscip Rev Nanomed Nanobiotechnol
Volume
9
Published Date
DOI
10.1002/wnan.1416

Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.

Authors
Zhang, T; Boominathan, R; Foulk, B; Connelly, MC; Rao, C; Kemeny, G; Strickler, JH; Abbruzzese, JL; Harrison, MR; George, DJ; Hurwitz, H; Garcia-Blanco, MA; Armstrong, AJ
MLA Citation
Zhang, Tian, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies..” Journal of Clinical Oncology, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.
URI
https://scholars.duke.edu/individual/pub1085415
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
33
Published Date

62CUATSM AND 62CUPTSM PET IS A USEFUL IMAGING TOOL FOR HYPOXIA AND PERFUSION IN LUNG CANCER

Authors
Zhang, T; Fels, DR; Hansen, KS; Das, SK; Wong, TZ; Dewhirst, MW; Vlahovic, G
MLA Citation
Zhang, Tian, et al. “62CUATSM AND 62CUPTSM PET IS A USEFUL IMAGING TOOL FOR HYPOXIA AND PERFUSION IN LUNG CANCER.” Journal of Thoracic Oncology, vol. 6, no. 6, LIPPINCOTT WILLIAMS & WILKINS, June 2011, pp. S919–20.
URI
https://scholars.duke.edu/individual/pub873401
Source
wos
Published In
Journal of Thoracic Oncology
Volume
6
Published Date
Start Page
S919
End Page
S920

Clinical utility of non-EpCAM based circulating tumor cell assays.

Methods enabling the isolation, detection, and characterization of circulating tumor cells (CTCs) in blood have clear potential to facilitate precision medicine approaches in patients with cancer, not only for prognostic purposes but also for prediction of the benefits of specific therapies in oncology. However, current CTC assays, which capture CTCs based on expression of epithelial cell adhesion molecule (EpCAM), fail to capture cells from de-differentiated tumors and carcinomas undergoing loss of the epithelial phenotype during the invasion/metastatic process. To address this limitation, many groups are developing non-EpCAM based CTC assays that incorporate nanotechnology to improve test sensitivity for rare but important cells that may otherwise go undetected, and therefore may improve upon clinical utility. In this review, we outline emerging non-EpCAM based CTC assays utilizing nanotechnology approaches for CTC capture or characterization, including dendrimers, magnetic nanoparticles, gold nanoparticles, negative selection chip or software-based on-slide methods, and nano-scale substrates. In addition, we address challenges that remain for the clinical translation of these platforms.
Authors
MLA Citation
Austin, R. Garland, et al. “Clinical utility of non-EpCAM based circulating tumor cell assays..” Adv Drug Deliv Rev, vol. 125, Feb. 2018, pp. 132–42. Pubmed, doi:10.1016/j.addr.2018.01.013.
URI
https://scholars.duke.edu/individual/pub1300102
PMID
29366804
Source
pubmed
Published In
Adv Drug Deliv Rev
Volume
125
Published Date
Start Page
132
End Page
142
DOI
10.1016/j.addr.2018.01.013